K
Kirsten Björnlinger
Publications - 4
Citations - 566
Kirsten Björnlinger is an academic researcher. The author has contributed to research in topics: Performance status & Prostate cancer. The author has an hindex of 3, co-authored 4 publications receiving 306 citations.
Papers
More filters
Journal ArticleDOI
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark,Adalsteinn Gunnlaugsson,Lars Beckman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Jon Kindblom,Claes Ginman,Bengt Johansson,Kirsten Björnlinger,Mihajl Seke,Måns Agrup,Per Fransson,Björn Tavelin,David Norman,Björn Zackrisson,Harald Anderson,Elisabeth Kjellén,Lars Franzén,Per Nilsson +19 more
TL;DR: There was weak evidence of an increased frequency of acute physician-reported RTOG grade 2 or worse urinary toxicity in the ultra-hypofractionation group at end of radiotherapy, consistent with the physician-evaluated toxicity.
Journal ArticleDOI
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Per Fransson,Per Nilsson,Adalsteinn Gunnlaugsson,Lars Beckman,Björn Tavelin,David Norman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Jon Kindblom,Claes Ginman,Bengt Johansson,Kirsten Björnlinger,Mihajl Seke,Måns Agrup,Björn Zackrisson,Elisabeth Kjellén,Lars Franzén,Anders Widmark +18 more
TL;DR: The HYPO-RT-PC trial as mentioned in this paper compared conventional fractionation and ultra-hypofractionation up to 6 years after treatment in patients with localised prostate cancer, and the results showed that UHF was non-inferior to traditional fractionation regarding 5-year failure-free survival and toxicity.
Journal ArticleDOI
Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer : Early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC"
Anders Widmark,Adalsteinn Gunnlaugsson,Lars Beckman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Per Fransson,Jon Kindblom,Claes Ginman,Bengt Johansson,Mihalj Seke,Kirsten Björnlinger,Elisabeth Kjellén,Lars Franzén,Per Nilsson +14 more
TL;DR: Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer and early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC" are presented.
Journal ArticleDOI
A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients.
Petter Brandal,Kjell Bergfeldt,Ninna Aggerholm-Pedersen,Gloria Bäckström,Irina Kerna,Michael Gubanski,Kirsten Björnlinger,Morten E. Evensen,Maire Kuddu,Erik Pettersson,Marianne Brydøy,Taran Paulsen Hellebust,Taran Paulsen Hellebust,Einar Dale,Alexander Valdman,Lars Weber,Morten Høyer +16 more
TL;DR: The patient selection process should be integrated into the radiotherapy community and emphasis on collaboration across medical specialties, involvement of key decision makers and knowledge dissemination in general are important factors.